Advertisement
AZTA or BIO or TMO
Which Stock Would AI Choose? Azenta (AZTA) vs. Bio-Rad Laboratories (BIO) vs. Thermo Fisher Scientific (TMO) Stock Comparison
Key Takeaways
- Scale separates the three names: TMO generates more than $45 billion in annual revenue, BIO roughly $2.6 billion, and AZTA closer to $600 million.
- Relative momentum currently favors TMO, which has posted strong quarterly results, raised guidance, and drawn a wave of higher analyst price targets.
- BIO offers a growth catalyst in digital PCR but trades at a premium valuation while broader life science demand remains uneven.
- AZTA is an early-stage turnaround, improving execution after a weak quarter while leaning on a debt-free balance sheet and a growing recurring-revenue base.
- All three are sensitive to the same macro cycle — academic, government, and biopharma research spending — making this a useful cross-section of the life science tools sector.
Introduction
Life science tools and diagnostics companies sit at the center of pharmaceutical research, drug development, and clinical testing, yet the three names compared here occupy very different positions in that ecosystem. AZTA is a focused sample-management and multiomics provider; BIO is a mid-sized specialist in research reagents and clinical diagnostics; and TMO is the industry's diversified leader. For investors and traders weighing relative performance and market positioning, this stock comparison highlights how scale, growth drivers, valuation sensitivity, and sentiment differ — and where an AI-driven signal might look for the most consistent trend.
AZTA Overview and Recent Performance
Azenta, Inc. provides cold-chain sample management, biorepository storage, and multiomics services, including gene synthesis and next-generation sequencing, for pharmaceutical, biotech, and academic customers. The company has been executing a multi-year transformation, and recent market activity reflects that transition. Earlier in its fiscal year, AZTA reported a disappointing quarter marked by execution gaps and softer North American demand, which pressured the shares. More recently, results improved: revenue rose double digits, both operating segments returned to organic growth, and adjusted earnings turned positive. Management has emphasized that more than half of revenue is now recurring in nature, supported by a balance sheet with no outstanding debt and a meaningful cash position. Investors continue to watch whether improved Multiomics execution and a shift toward modular, standardized automated storage products can sustain momentum.
BIO Overview and Recent Performance
Bio-Rad Laboratories, Inc. develops life science research tools and clinical diagnostics products, including quality controls, blood typing, and diabetes testing. In recent weeks, BIO shares have outperformed, gaining roughly double digits over the past month, driven largely by strength in its digital PCR (polymerase chain reaction) franchise. Digital PCR instrument revenue has grown at a strong clip as the company converts customers from traditional PCR and integrates its Stilla acquisition. That growth engine, however, is offset by softer academic research spending and a recurring-revenue diagnostics business that has been constrained by geopolitical disruption in the Middle East. Full-year guidance calls for currency-neutral revenue roughly flat to slightly down, and the stock trades near 40 times forward earnings — a premium to both its peer group and its own historical median. A restructuring program aimed at annualized cost savings underpins management's path toward margin expansion.
TMO Overview and Recent Performance
Thermo Fisher Scientific Inc. is the world's largest life science tools company, spanning analytical instruments, reagents and consumables, specialty diagnostics, and contract pharma services through its Patheon and PPD brands. Recent market activity has favored TMO, with the stock posting strong three-month gains and a broad rally in analyst sentiment. The company beat earnings expectations in its most recent quarters, raised full-year guidance for both revenue and adjusted earnings per share (EPS), and continues to deploy capital through acquisitions such as Clario, a clinical-trial endpoint data provider, while divesting its microbiology business. A 10% dividend increase and substantial share repurchases further signal management confidence. With pharma and biotech customers representing roughly 60% of revenue, improving funding conditions have become a key driver, though some analysts caution that a meaningful portion of that recovery may already be reflected in the share price.
Trending AI Robots
For traders who prefer a systematic approach to this kind of stock comparison, Tickeron's Trending AI Robots page curates a selection of AI trading bots designed for current market conditions. Tickeron offers hundreds of AI Trading Bots that together trade thousands of different tickers, each with its own trading style, strategy, timeframe, performance statistics, and set of underlying securities. Because strategies that worked in one regime can struggle in another, only the best-performing and most suitable bots earn a place in this curated section, with statistics spanning win rates, trade frequency, and drawdown characteristics. Browsing the Trending AI Robots page can help traders identify which automated strategies are currently aligned with momentum in names like these.
Head-to-Head Comparison
At the most basic level, these three companies differ by business model and diversification. TMO is a diversified, recession-resilient leader with recurring consumables and pharma services; BIO balances a cyclical research tools business against a steadier diagnostics base; and AZTA is a more concentrated, higher-beta turnaround. On recent momentum, TMO leads with guidance raises and rising targets, while BIO has rallied on digital PCR even as its valuation expands, and AZTA is rebuilding credibility after a volatile stretch. Risk factors also differ: AZTA faces execution and capital-equipment cycle risk, BIO contends with academic funding softness and geopolitical exposure, and TMO carries the integration and dilution risks of large acquisitions alongside a premium multiple. From a valuation sensitivity standpoint, AZTA trades on turnaround expectations, BIO on an above-median earnings multiple, and TMO slightly above its own historical ratio but below some sector benchmarks. Sentiment is most constructive around TMO, more mixed on BIO, and cautiously recovering on AZTA.
Tickeron AI Verdict
Based on observable factors — trend consistency, earnings momentum, guidance direction, and the breadth of analyst support — Tickeron's AI would most likely favor TMO among the three. Its combination of consistent quarterly beats, upwardly revised guidance, diversified revenue streams, and improving pharma and biotech end markets presents the most stable and confirmable trend signature. BIO offers an attractive digital PCR catalyst but carries a richer valuation and more uneven demand, while AZTA shows improving fundamentals but a shorter, less established track record of consistent execution. This assessment is probabilistic rather than definitive: relative positioning can shift quickly as earnings, funding conditions, and sentiment evolve.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
AZTA in -8.31% downward trend, declining for three consecutive days on October 16, 2026
Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where AZTA declined for three days, in 262 of 324 cases, the price declined further within the following month. The odds of a continued downward trend are 81%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The 10-day RSI Indicator for AZTA moved out of overbought territory on October 06, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 31 similar instances where the indicator moved out of overbought territory. In 25 of the 31 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.
The Momentum Indicator moved below the 0 level on October 23, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on AZTA as a result. In 63 of 86 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 73%.
The Moving Average Convergence Divergence Histogram (MACD) for AZTA turned negative on October 15, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 49 similar instances when the indicator turned negative. In 36 of the 49 cases the stock turned lower in the days that followed. This puts the odds of success at 73%.
AZTA broke above its upper Bollinger Band on October 02, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Bullish Trend Analysis
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 43 of 62 cases where AZTA's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 69%.
AZTA moved above its 50-day moving average on October 19, 2026 date and that indicates a change from a downward trend to an upward trend.
Following a +5.51% 3-day Advance, the price is estimated to grow further. Considering data from situations where AZTA advanced for three days, in 215 of 299 cases, the price rose further within the following month. The odds of a continued upward trend are 72%.
The Aroon Indicator entered an Uptrend today. In 151 of 177 cases where AZTA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 85%.
Fundamental Analysis (Ratings)
The Tickeron Valuation Rating of 13 (best 1 - 100 worst) indicates that the company is seriously undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.059) is normal, around the industry mean (4.994). P/E Ratio (-13.569) is within average values for comparable stocks, (37.175). Projected Growth (PEG Ratio) (0.310) is also within normal values, averaging (4.143). Dividend Yield (0.011) settles around the average of (0.005) among similar stocks. P/S Ratio (2.485) is also within normal values, averaging (56.876).
The Tickeron Price Growth Rating for this company is 38 (best 1 - 100 worst), indicating steady price growth. AZTA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 93 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Seasonality Score of 95 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. AZTA’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
BIO's RSI Indicator ascends from oversold territory
The RSI Oscillator for BIO moved out of oversold territory on October 02, 2026. This could be a sign that the stock is shifting from a downward trend to an upward trend. Traders may want to buy the stock or call options. The A.I.dvisor looked at 28 similar instances when the indicator left oversold territory. In 22 of the 28 cases the stock moved higher. This puts the odds of a move higher at 79%.
Technical Analysis (Indicators)
Bullish Trend Analysis
The Momentum Indicator moved above the 0 level on October 22, 2026. You may want to consider a long position or call options on BIO as a result. In 67 of 96 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 70%.
The Moving Average Convergence Divergence (MACD) for BIO just turned positive on October 23, 2026. Looking at past instances where BIO's MACD turned positive, the stock continued to rise in 34 of 51 cases over the following month. The odds of a continued upward trend are 67%.
Following a +2.62% 3-day Advance, the price is estimated to grow further. Considering data from situations where BIO advanced for three days, in 194 of 300 cases, the price rose further within the following month. The odds of a continued upward trend are 65%.
BIO may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
Bearish Trend Analysis
The Stochastic Oscillator entered the overbought zone. Expect a price pull-back in the foreseeable future.
BIO moved below its 50-day moving average on October 07, 2026 date and that indicates a change from an upward trend to a downward trend.
The 10-day moving average for BIO crossed bearishly below the 50-day moving average on October 12, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 14 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 71%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where BIO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 69%.
The Aroon Indicator for BIO entered a downward trend on October 12, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 10 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 44 (best 1 - 100 worst), indicating steady price growth. BIO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 87 (best 1 - 100 worst), indicating slightly better than average sales and a considerably profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 93 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.379) is normal, around the industry mean (2.914). P/E Ratio (44.951) is within average values for comparable stocks, (1.904). Projected Growth (PEG Ratio) (4.006) is also within normal values, averaging (11.052). Dividend Yield (0.000) settles around the average of (0.009) among similar stocks. P/S Ratio (3.940) is also within normal values, averaging (40.124).
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. BIO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.
Momentum Indicator for TMO turns positive, indicating new upward trend
TMO saw its Momentum Indicator move above the 0 level on October 15, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 88 similar instances where the indicator turned positive. In 56 of the 88 cases, the stock moved higher in the following days. The odds of a move higher are at 64%.
Technical Analysis (Indicators)
Bullish Trend Analysis
Following a +2.15% 3-day Advance, the price is estimated to grow further. Considering data from situations where TMO advanced for three days, in 194 of 310 cases, the price rose further within the following month. The odds of a continued upward trend are 63%.
The Aroon Indicator entered an Uptrend today. In 142 of 246 cases where TMO Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 58%.
Bearish Trend Analysis
The 10-day RSI Indicator for TMO moved out of overbought territory on October 01, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 37 similar instances where the indicator moved out of overbought territory. In 19 of the 37 cases, the stock moved lower in the following days. This puts the odds of a move lower at 51%.
The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In 38 of 66 cases where TMO's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are 58%.
The Moving Average Convergence Divergence Histogram (MACD) for TMO turned negative on October 22, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 43 similar instances when the indicator turned negative. In 23 of the 43 cases the stock turned lower in the days that followed. This puts the odds of success at 53%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where TMO declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 62%.
TMO broke above its upper Bollinger Band on October 15, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
Fundamental Analysis (Ratings)
The Tickeron Price Growth Rating for this company is 16 (best 1 - 100 worst), indicating outstanding price growth. TMO’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 27 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 50 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 60 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of 65 (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.729) is normal, around the industry mean (66.137). P/E Ratio (36.207) is within average values for comparable stocks, (2.464). Projected Growth (PEG Ratio) (2.021) is also within normal values, averaging (3.473). Dividend Yield (0.003) settles around the average of (0.002) among similar stocks. P/S Ratio (5.247) is also within normal values, averaging (9.775).
The Tickeron Profit vs. Risk Rating rating for this company is 77 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. TMO’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 88, placing this stock better than average.
AZTA | BIO | TMO | ||
|---|---|---|---|---|
OUTLOOK RATING 1..100 | 86 | 74 | 33 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 13 Undervalued | 93 Overvalued | 65 Fair valued | |
PROFIT vs RISK RATING 1..100 | 100 | 100 | 77 | |
SMR RATING 1..100 | 93 | 87 | 60 | |
PRICE GROWTH RATING 1..100 | 38 | 44 | 16 | |
P/E GROWTH RATING 1..100 | 97 | 10 | 27 | |
SEASONALITY SCORE 1..100 | 90 | 50 | 50 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
AZTA's Valuation (13) in the Electronic Production Equipment industry is somewhat better than the same rating for TMO (65) in the Medical Specialties industry, and is significantly better than the same rating for BIO (93) in the Medical Specialties industry. This means that AZTA's stock grew somewhat faster than TMO’s and significantly faster than BIO’s over the last 12 months.
TMO's Profit vs Risk Rating (77) in the Medical Specialties industry is in the same range as AZTA (100) in the Electronic Production Equipment industry, and is in the same range as BIO (100) in the Medical Specialties industry. This means that TMO's stock grew similarly to AZTA’s and similarly to BIO’s over the last 12 months.
TMO's SMR Rating (60) in the Medical Specialties industry is in the same range as BIO (87) in the Medical Specialties industry, and is somewhat better than the same rating for AZTA (93) in the Electronic Production Equipment industry. This means that TMO's stock grew similarly to BIO’s and somewhat faster than AZTA’s over the last 12 months.
TMO's Price Growth Rating (16) in the Medical Specialties industry is in the same range as AZTA (38) in the Electronic Production Equipment industry, and is in the same range as BIO (44) in the Medical Specialties industry. This means that TMO's stock grew similarly to AZTA’s and similarly to BIO’s over the last 12 months.
BIO's P/E Growth Rating (10) in the Medical Specialties industry is in the same range as TMO (27) in the Medical Specialties industry, and is significantly better than the same rating for AZTA (97) in the Electronic Production Equipment industry. This means that BIO's stock grew similarly to TMO’s and significantly faster than AZTA’s over the last 12 months.
| AZTA | BIO | TMO | |
|---|---|---|---|
| RSI ODDS (%) | 1 day ago 81% | 1 day ago 79% | 1 day ago 51% |
| Stochastic ODDS (%) | 1 day ago 69% | 1 day ago 79% | 1 day ago 58% |
| Momentum ODDS (%) | 1 day ago 73% | 1 day ago 70% | 1 day ago 64% |
| MACD ODDS (%) | 1 day ago 73% | 1 day ago 67% | 1 day ago 53% |
| TrendWeek ODDS (%) | 1 day ago 72% | 1 day ago 66% | 1 day ago 60% |
| TrendMonth ODDS (%) | 1 day ago 76% | 1 day ago 73% | 1 day ago 62% |
| Advances ODDS (%) | 4 days ago 72% | 1 day ago 65% | 4 days ago 63% |
| Declines ODDS (%) | 9 days ago 81% | 6 days ago 69% | 1 day ago 62% |
| BollingerBands ODDS (%) | 1 day ago 76% | 1 day ago 77% | 1 day ago 57% |
| Aroon ODDS (%) | 1 day ago 85% | 1 day ago 76% | 1 day ago 58% |
Long-Term Analysis
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
AZTA’s FA Score shows that 1 FA rating(s) are green while BIO’s FA Score has 1 green FA rating(s), and TMO’s FA Score reflects 2 green FA rating(s).
- AZTA’s FA Score: 1 green, 4 red.
- BIO’s FA Score: 1 green, 4 red.
- TMO’s FA Score: 2 green, 3 red.
Short-Term Analysis
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
AZTA’s TA Score shows that 4 TA indicator(s) are bullish while BIO’s TA Score has 5 bullish TA indicator(s), and TMO’s TA Score reflects 3 bullish TA indicator(s).
- AZTA’s TA Score: 4 bullish, 5 bearish.
- BIO’s TA Score: 5 bullish, 5 bearish.
- TMO’s TA Score: 3 bullish, 5 bearish.
Price Growth
AZTA (@Pharmaceuticals: Other) experienced а +7.07% price change this week, while BIO (@Medical/Nursing Services) price change was +4.59% , and TMO (@Medical Specialties) price fluctuated -2.34% for the same time period.
The average weekly price growth across all stocks in the @Pharmaceuticals: Other industry was +2.78%. For the same industry, the average monthly price growth was -3.41%, and the average quarterly price growth was +7.38%.
The average weekly price growth across all stocks in the @Medical/Nursing Services industry was -0.51%. For the same industry, the average monthly price growth was -9.72%, and the average quarterly price growth was -10.64%.
The average weekly price growth across all stocks in the @Medical Specialties industry was +1.55%. For the same industry, the average monthly price growth was -5.91%, and the average quarterly price growth was +42.02%.
Reported Earning Dates
AZTA is expected to report earnings on Nov 20, 2026.
BIO is expected to report earnings on Nov 04, 2026.
TMO is expected to report earnings on Feb 04, 2027.
Industries' Descriptions
@Pharmaceuticals: Other (+2.78% weekly)Pharmaceuticals (Other) comprise companies that are involved in the discovery, development or manufacturing of therapeutic and preventative medicines. They often collaborate with or acquire other pharmaceutical/healthcare firms. Examples of companies in this segment include Bausch Health Companies Inc., Icon Plc and Perrigo Company Plc.
@Medical/Nursing Services (-0.51% weekly)The medical/nursing services includes companies that provide medical-related services such as ambulance services, dialysis centers, respiratory therapy, blood testing and rehabilitation services. DaVita Inc., Chemed Corporation and Guardant Health, Inc. are examples of companies in this industry.
@Medical Specialties (+1.55% weekly)Medical specialties are companies that make equipment used by the health care industry. Equipment manufactured and distributed by these companies include dialysis machines, blood analysis equipment, surgical equipment, dental instruments, and diagnostic tools, among other items. Large companies typically aim to produce and distribute high-quality products across a broad market spectrum. Smaller firms are more likely to specialize in a particular market segment. Due to the industry’s close association with medical treatments, they typically have low sensitivity to macroeconomic fluctuations. Within this industry, Abbott Laboratories, Medtronic Plc and Thermo Fisher Scientific Inc. are some of the companies with multi-billion market capitalizations in the U.S. stock markets.
Advertisement
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| VTEB | 48.51 | 0.10 | +0.21% |
| Vanguard Tax-Exempt Bond ETF (VTEB) | |||
| SPUT | 28.58 | -0.05 | -0.17% |
| Innovator Daily PutWrite ETF (SPUT) | |||
| HLAL | 72.51 | -0.20 | -0.28% |
| Wahed FTSE USA Shariah ETF (HLAL) | |||
| GTR | 27.07 | -0.09 | -0.35% |
| WisdomTree Target Range Fund (GTR) | |||
| PKB | 85.44 | -1.15 | -1.33% |
| Invesco Building & Construction ETF (PKB) | |||
AZTA and
Correlation & Price change
A.I.dvisor indicates that over the last year, AZTA has been loosely correlated with IQV. These tickers have moved in lockstep 60% of the time. This A.I.-generated data suggests there is some statistical probability that if AZTA jumps, then IQV could also see price increases.
| Ticker / NAME | Correlation To AZTA | 1D Price Change % | ||
|---|---|---|---|---|
| AZTA | 100% | +1.36% | ||
| IQV - AZTA | 60% Loosely correlated | +0.37% | ||
| RVTY - AZTA | 59% Loosely correlated | +0.94% | ||
| A - AZTA | 59% Loosely correlated | -0.47% | ||
| MTD - AZTA | 59% Loosely correlated | -0.85% | ||
| BRKR - AZTA | 58% Loosely correlated | +0.49% | ||
More | ||||
TMO and
Correlation & Price change
A.I.dvisor indicates that over the last year, TMO has been closely correlated with A. These tickers have moved in lockstep 74% of the time. This A.I.-generated data suggests there is a high statistical probability that if TMO jumps, then A could also see price increases.
| Ticker / NAME | Correlation To TMO | 1D Price Change % | ||
|---|---|---|---|---|
| TMO | 100% | -0.40% | ||
| A - TMO | 74% Closely correlated | -0.47% | ||
| DHR - TMO | 71% Closely correlated | +0.33% | ||
| RVTY - TMO | 69% Closely correlated | +0.94% | ||
| IQV - TMO | 68% Closely correlated | +0.37% | ||
| BRKR - TMO | 67% Closely correlated | +0.49% | ||
More | ||||